Literature DB >> 16967511

Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein.

Hoau-Yan Wang1, Lindsay H Burns.   

Abstract

We previously demonstrated that chronic morphine induces a change in G protein coupling by the mu opioid receptor (MOR) from Gi/o to Gs, concurrent with the instatement of an interaction between Gbetagamma and adenylyl cyclase types II and IV. These two signaling changes confer excitatory effects on the cell in place of the typical inhibition by opioids and are associated with morphine tolerance and dependence. Both signaling changes and these behavioral manifestations of chronic morphine are attenuated by cotreatment with ultra-low-dose naloxone. In the present work, using striatum from chronic morphine-treated rats, we isotyped the Gbeta within Gs and Go heterotrimers that coupled to MOR and compared these to the Gbeta isotype of the Gbetagamma that interacted with adenylyl cyclase II or IV after chronic morphine treatment. Isotyping results show that chronic morphine causes a Gs heterotrimer associated with MOR to release its Gbetagamma to interact with adenylyl cyclase. These data suggest that the switch to Gs coupling by MOR in response to chronic morphine, which is attenuated by ultra-low-dose opioid antagonist cotreatment, leads to a two-pronged stimulation of adenylyl cyclase utilizing both Galpha and Gbetagamma subunits of the Gs protein novel to this receptor. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16967511     DOI: 10.1002/neu.20286

Source DB:  PubMed          Journal:  J Neurobiol        ISSN: 0022-3034


  20 in total

1.  Shared mechanisms for opioid tolerance and a transition to chronic pain.

Authors:  Elizabeth K Joseph; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

4.  Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats.

Authors:  Ilona Obara; Ozge Gunduz Cinar; Katarzyna Starowicz; Sandor Benyhe; Anna Borsodi; Barbara Przewlocka
Journal:  J Neural Transm (Vienna)       Date:  2010-03-06       Impact factor: 3.575

Review 5.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 6.  Regulation by Ca2+-signaling pathways of adenylyl cyclases.

Authors:  Michelle L Halls; Dermot M F Cooper
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 7.  μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.

Authors:  Marino Convertino; Alexander Samoshkin; Josee Gauthier; Michael S Gold; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-12-06       Impact factor: 5.067

8.  Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors.

Authors:  Jillian L Scavone; Ken Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2009-11-18       Impact factor: 3.252

9.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors:  Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal:  J Pain       Date:  2008-05-12       Impact factor: 5.820

10.  Tolerance to repeated morphine administration is associated with increased potency of opioid agonists.

Authors:  Susan L Ingram; Tara A Macey; Erin N Fossum; Michael M Morgan
Journal:  Neuropsychopharmacology       Date:  2007-11-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.